Advertisement

Topics

Patients on infliximab seen as less likely to remain on treatment than etanercept

06:06 EDT 19 Jun 2017 | Healio

MADRID — Patients on infliximab as their first biologic were less likely to remain on treatment compared with patients on etanercept, according to an analysis presented at EULAR Annual Congress.“Patients with [rheumatoid arthritis] RA starting infliximab as their first biologic [disease-modified antirheumatic drug] DMARD were less likely to remain on treatment with significant improvement at 1 year compared to those initiating etanercept,” Carl Turesson, MD, from Lund University in Sweden, said in his presentation.

Original Article: Patients on infliximab seen as less likely to remain on treatment than etanercept

NEXT ARTICLE

More From BioPortfolio on "Patients on infliximab seen as less likely to remain on treatment than etanercept"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Orthopedics
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...